Expert Interviews

Panelists discuss how CAR T therapy has transformed the treatment landscape for relapsed/refractory multiple myeloma, highlighting critical factors for success including patient selection, timing of referral, management of adverse effects, and the importance of coordinated care between academic centers and community practices.

Panelists discuss how isatuximab- and daratumumab-based quadruplet regimens compare in patients with transplant-ineligible/deferred newly diagnosed multiple myeloma (NDMM), with a particular focus on minimal residual disease (MRD) negativity data from the IMROZ and CEPHEUS trials, presented at the 2024 American Society of Hematology (ASH) Annual Meeting and Exposition.

Panelists discuss how they would approach a challenging case of a 68-year-old man with high-risk relapsed/refractory multiple myeloma who has progressed after stem cell transplantation, considering factors such as prior treatments, cytogenetic profile, and current fitness status to determine optimal next-line therapy options.

Panelists discuss how treatment strategies and sequencing decisions for patients with multiple myeloma who decline transplantation despite eligibility must be carefully tailored, considering both immediate therapeutic goals and potential future treatment options.

“We have huge amounts of work to do to maximize the efficacy of immunotherapy,” Christine Bestvina, MD, said during an interview with CancerNetwork.

Panelists discuss how successful academic-community partnerships in delivering chimeric antigen receptor (CAR) T-cell therapy for multiple myeloma patients have evolved through shared learning experiences, established communication pathways, and continuous refinement of collaborative care protocols.

Dr. Garon explains the factors guiding his choice between EGFR inhibitors for EGFR+ NSCLC and when he might consider alternatives like afatinib or erlotinib.

Christine Bestvina, MD, stated that the presence of EGFR and ALK mutations can affect the way that a patient will react to treatment and should be factors that physicians consider.

“We need some longer-term overall survival data to help discuss with patients the best treatment of choice for them,” Christine Bestvina, MD, said.

In this segment, Dr Mohan asks Dr Mann about emerging investigational agents for the management of relapsed/refractory multiple myeloma (R/R MM) that show particular promise.

In this segment, Dr Mohan asks Dr Nadeem about the real-world performance of elranatamab, its advantages and challenges in clinical practice, and the next therapeutic approach if a patient experiences disease progression on elranatamab.

Additional local, regional, or national policy may bolster access to screening for colorectal cancer, according to Aasma Shaukat, MD, MPH.

Panelists discuss how Julia prepares patients for treatment with amivantamab, including educating them on potential side effects and incorporating proactive strategies into treatment management to optimize patient care and minimize adverse effects.

Panelists discuss the shared decision-making process following Melinda's evaluation, with Dr. Spira explaining the factors that led to recommending the MARIPOSA2 regimen, while Melinda shares her active role in participating in the decision-making process regarding her treatment.

Panelists discuss at what line of therapy bispecific antibodies are considered in treatment decision-making, whether they are used earlier or later in the sequence, and the factors influencing that choice, including weighing bispecifics against other options like chimeric antigen receptor (chimeric antigen receptor) T or standard therapies. They also address the clinical and molecular factors that guide the selection between B-cell maturation antigen (BCMA)– and GPRC5D-targeting bispecifics and comment on the study exploring talquetamab as a bridging strategy before BCMA CAR T therapy, highlighting the potential impact of bispecifics in this treatment paradigm.

Panelists discuss how treatment-emergent adverse events were comparable among patients treated with subcutaneous amivantamab-lazertinib vs intravenous administration in the PALOMA-3 trial.

Panelists discuss how PALOMA-3’s pharmacokinetic and secondary end point analyses demonstrated the clinical benefit of palbociclib through multiple measures, including progression-free survival, objective response rate, and drug concentration levels that inform optimal dosing strategies.

Panelists discuss how bispecific antibodies are reshaping the therapeutic approach in relapsed/refractory multiple myeloma (R/R MM), covering their mechanism of action, currently approved agents, and potential advantages. They explore how these therapies have transformed clinical decision-making, including optimal lines of therapy, patient selection, and best practices for integrating bispecifics into clinical practice.

The mechanism of action for daraxonrasib inhibits effectors and signaling while forming a relatively unstable tri-complex with codon 12 mutations.